ImpediMed Limited, together with its subsidiaries, develops, manufactures, and sells bioimpedance instruments, consumables, and software in Australia, North America, and internationally. The company operates through Medical and Test & Measurement segments. It offers SOZO, a next generation bioimpedance spectroscopy digital health platform; and L-Dex U400, a technology that utilizes the characteristics of frequency dependent current flow to quantify changes in extracellular fluid in the patient's limb. The company also provides SFB7, a tetra polar bioimpedance spectroscopy device that scans various frequencies for the estimation of body composition in healthy individuals; and ImpediVET, a bioimpedance spectroscopy technology for use in veterinary applications. In addition, the company supplies power precision testing and measuring equipment. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 7 3860 3700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.08 million
Profitability
Miscellaneous
Employees68
Next Earnings DateN/A
OptionableNot Optionable
Impedimed (ASX:IPD) Frequently Asked Questions
What is Impedimed's stock symbol?
Impedimed trades on the ASX under the ticker symbol "IPD."
Has Impedimed been receiving favorable news coverage?
Headlines about IPD stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Impedimed earned a coverage optimism score of 1.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are some of Impedimed's key competitors?
Some companies that are related to Impedimed include Creo Medical Group (CREO), Medica Group (MGP), Hamilton Thorne (HTL), Titan Medical (TMD), Advanced Oncotherapy (AVO), Cyclopharm (CYC), Helius Medical Technologies (HSM), Kromek Group (KMK), REVA Medical (RVA), Osprey Medical (OSP), Resonance Health (RHT), Protech Home Medical (PHM), Electromed (ELMD), Universal Biosensors (UBI) and Surgical Innovations Group (SUN).
Who are Impedimed's key executives?
Impedimed's management team includes the folowing people:
- Mr. Richard Carreon, MD, CEO, Pres & Exec. Director
- Mr. Morten Vigeland, Chief Financial Officer
- Mr. David Michae Adams J.D., BSc, Sr. VP of Ventures, Licensing & Corp. Devel.
- Mr. Dennis Schlaht, Sr. VP of R&D and Technology
- Ms. Catherine Kingsford, Sr. VP of Medical Affairs
What is Impedimed's stock price today?
One share of IPD stock can currently be purchased for approximately A$0.21.
How big of a company is Impedimed?
Impedimed has a market capitalization of $79.75 million and generates $5.08 million in revenue each year. Impedimed employs 68 workers across the globe.
What is Impedimed's official website?
How can I contact Impedimed?
The company can be reached via phone at 61 7 3860 3700.
MarketBeat Community Rating for Impedimed (ASX IPD)
MarketBeat's community ratings are surveys of what our community members think about Impedimed and other stocks. Vote "Outperform" if you believe IPD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPD will underperform the S&P 500 over the long term. You may vote once every thirty days.
